Breaking Finance News

Concordia Healthcare Corp (NASDAQ:CXRX) has been upgraded from Underperform to Sector Perform in a statement by Scotia Capital earlier today.

Only yesterday Concordia Healthcare Corp (NASDAQ:CXRX) traded 1.20% lower at $5.34. CXRX’s 50-day average is $11.61 and its two hundred day average is $22.48. With the last close down 76.27% from the two hundred day average, compared to the S&P 500 Index which has fallen -0.01% over the same time. Volume of trade was was down over the average, with 702,461 shares of CXRX changing hands under the typical 848,814 shares..

Scotia Capital has upgraded Concordia Healthcare Corp(NASDAQ:CXRX) from Underperform to Sector Perform in a statement released 9/19/2016.

See Graph Below:

Concordia Healthcare Corp (NASDAQ:CXRX)

A total of 10 brokerages have reported on the stock. Zero rate the company a strong buy, 0 rate the company a buy, 0 firms rate the stock a hold, 0 rate the company to underperform, and lastly 0 analystsrate the stock as sell with a consensus target stock price of $52.01

Concordia Healthcare Corp has a one-year low of $5.01 and a one-year high of $76.10. The company’s market cap is presently $0.0.

Brief Synopsis About Concordia Healthcare Corp (NASDAQ:CXRX)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *